Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Moderna sees 20 million doses of COVID-19 vaccine candidate by year end

share with twitter share with LinkedIn share with facebook
09/18/2020 | 01:14pm EDT

Moderna Inc said on Friday it was on track to produce 20 million doses of its experimental coronavirus vaccine by the end of the year, while maintaining its goal of readying 500 million to 1 billion doses in 2021.

Vaccines and treatments are seen as essential in controlling the COVID-19 pandemic that has shown no signs of slowing and killed over 944,000 people worldwide.

A handful of vaccines, including those from Pfizer Inc and AstraZeneca, are also being tested in large studies.

Moderna had enrolled 25,296 participants out of a planned 30,000 in its late-stage study as of Wednesday. (https://bit.ly/35PkSnc)

The company is working with Switzerland's Lonza Group AG and Spain's Laboratorios Farmacéuticos Rovi to make the vaccine outside the United States.

Moderna has a vaccine supply deal in place with the U.S. for 100 million doses, and has finished advanced talks with the European Union for the vaccine.

The Centers for Disease Control and Prevention anticipates that 35 million to 45 million doses of vaccines from the first two companies to receive authorization will be available in the United States by the end of this year.

Moderna plans to seek emergency authorization for its vaccine's use in high-risk groups if it proves to be at least 70% effective, its chief executive officer told Reuters earlier this week.

(Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)


Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.26% 8056 Delayed Quote.6.18%
LONZA GROUP AG 0.59% 577.8 Delayed Quote.62.63%
MODERNA, INC. -0.40% 69.9238 Delayed Quote.259.10%
PFIZER INC. -0.65% 37.709 Delayed Quote.-3.22%
PFIZER LIMITED -0.97% 5137.8 End-of-day quote.21.63%
share with twitter share with LinkedIn share with facebook
All news about MODERNA, INC.
12:36pEU warns not enough COVID vaccines for all in Europe until 2022
RE
12:36pUK starts real-time review of Moderna's COVID-19 vaccine candidate
RE
12:34pPfizer says no COVID-19 vaccine data yet, could be week or more before it rep..
RE
11:53aPfizer Says Covid-19 Vaccine Late-Stage Trial Almost Fully Enrolled -- 2nd Up..
DJ
09:58aMODERNA : UK starts real-time review of Moderna's COVID-19 vaccine candidate
RE
09:47aMODERNA : Announces Supply Agreement with the Ministry of Public Health to Suppl..
AQ
09:13aMODERNA : UK Medicines and Healthcare products Regulatory Agency Begins Rolling ..
BU
08:14aPandemic Dents Third-Quarter Sales for Pfizer -- Update
DJ
06:58aPfizer says no COVID-19 vaccine data yet, could be week or more before it rep..
RE
10/26MODERNA : Announces Supply Agreement with the Ministry of Public Health to Suppl..
BU
More news
Financials (USD)
Sales 2020 305 M - -
Net income 2020 -537 M - -
Net cash 2020 2 553 M - -
P/E ratio 2020 -49,3x
Yield 2020 -
Capitalization 27 716 M 27 716 M -
EV / Sales 2020 82,5x
EV / Sales 2021 4,94x
Nbr of Employees 975
Free-Float 89,8%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 91,47 $
Last Close Price 70,24 $
Spread / Highest target 93,6%
Spread / Average Target 30,2%
Spread / Lowest Target -41,6%
EPS Revisions
Managers
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.259.10%27 716
LONZA GROUP AG62.63%47 039
SEAGEN INC.71.39%34 074
IQVIA HOLDINGS INC.4.96%31 092
CELLTRION, INC.32.04%28 087
IMMUNOMEDICS, INC.315.22%20 324